Cited by 97Viral Infectious Diseases and Gene Expression in InsectsMicrobial Metabolic Engineering and BioproductionProtein purification and stability

CHO-omics review: the impact of current and emerging technologies on Chinese hamster ovary based bioproduction

Stolfa, Gino, Smonskey, Matthew T., Boniface, Ryan, Hachmann, Anna‐Barbara, Gulde, Paul, Joshi, Atul D., Pierce, Anson P., Jacobia, Scott J. +1 more·2018·Biotechnology Journal

Abstract

CHO cells are the most prevalent platform for modern bio-therapeutic production. Currently, there are several CHO cell lines used in bioproduction with distinct characteristics and unique genotypes and phenotypes. These differences limit advances in productivity and quality that can be achieved by the most common approaches to bioprocess optimization and cell line engineering. Incorporating omics-based approaches into current bioproduction processes will complement traditional methodologies to maximize gains from CHO engineering and bioprocess improvements. In order to highlight the utility of omics technologies in CHO bioproduction, the authors discuss current applications as well as limitations of genomics, transcriptomics, proteomics, metabolomics, lipidomics, fluxomics, glycomics, and multi-omics approaches and the potential they hold for the future of bioproduction. Multiple omics approaches are currently being used to improve CHO bioprocesses; however, the application of these technologies is still limited. As more CHO-omic datasets become available and integrated into systems models, the authors expect significant gains in product yield and quality. While individual omics technologies provide incremental improvements in bioproduction, the authors will likely see the most significant gains by applying multi-omics and systems biology approaches to individual CHO cell lines.

Integrity signals

Registry

Crossref · 10.1002/biot.201700227

Cites

161 of 161 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Advances in various omics technologies have significantly improved understanding of CHO cells at different levels and enabled rational targeting of glycosylation effectors for improved biopharmaceutical production.

    “Advances in various omics technologies have significantly improved our understanding of CHO cells at different levels and enabled the rational targeting of glycosylation effectors for improved biopharmaceutical production [27,71,72,150–152].”

    From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [152]

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Stolfa, G., Smonskey, M. T., Boniface, R., Hachmann, A., Gulde, P., Joshi, A. D., Pierce, A. P., Jacobia, S. J., & Campbell, A.
Affiliations
Thermo Fisher Scientific (United States) (US)
Corresponding author
Smonskey, Matthew T.
Venue
Biotechnology Journal
Publisher
Wiley
Published
2017-11-15
Volume
13
Issue
3
Pages
e1700227-e1700227
ISSN
  • 1860-6768 (ISSN-L)
  • 1860-7314
OpenAlex
W2765517019
Cited by
97
References
161
Citations by year
2026: 4 · 2025: 14 · 2024: 8 · 2023: 12 · 2022: 12 · 2021: 15 · 2020: 16 · 2019: 6 · 2018: 9
FWCI
0.79
Type
journal article
Language
en
Open access
closed
Locations
  • Biotechnology Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Microbial Metabolic Engineering and Bioproduction
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Keywords
CHO cells, biopharmaceutical manufacturing, omics technologies, multi-omics, cell line engineering, bioprocess optimization, transcriptomics, proteomics, metabolomics, lipidomics, fluxomics, glycomics, systems biology, recombinant protein expression
MeSH terms
Animals, Cricetulus, Humans, CHO Cells, Genomics, Proteomics, Systems Biology, Glycomics, Metabolomics, Cell Engineering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review